CALL - SPRINTER OPEN END - GILEAD SCIENCES | Delayed Deutsche Boerse AG 04:17:01 2024-05-23 am EDT | ||
| 1.02 EUR | -1.92% |
|
| 1 month | -2.80% | ||
| 3 months | -32.90% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-23 | 1.02 | -1.92% |
| 24-05-22 | 1.04 | +6.12% |
| 24-05-21 | 0.98 | -7.55% |
| 24-05-20 | 1.06 | +1.92% |
| 24-05-17 | 1.04 | -0.95% |
Delayed Quote Deutsche Boerse AG
Last update May 23, 2024 at 04:17 am EDT
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VP8CKE |
| ISIN | DE000VP8CKE5 |
| Date issued | 2020-09-17 |
| Strike | 56.74 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.46 € |
|---|---|
| Lowest since issue | 0.42 € |
| Spread | 0.03 € |
| Spread % | 2.88% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
67.8
USD
Average target price
82.93
USD
Spread / Average Target
+22.31%
- Stock Market
- Certificates
- Certificat
